Condition
Postmenopausal Women With Advanced Breast Cancer
Total Trials
3
Recruiting
0
Active
0
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
1 treatments under study, led by Letrozole
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.4% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 3 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
3Total
Phase 2 (3)
Trial Status
Completed3
Trial Success Rate
100.0%
Benchmark: 86.6%
Based on 3 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT00237211Phase 2CompletedPrimary
Study of High-dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer
NCT00237198Phase 2CompletedPrimary
Study of Safety and Efficacy of Letrozole Monotherapy as Second-line Endocrine Therapy in Postmenopausal Patients With Advanced Breast Cancer Who Received Previous Anti-estrogen Treatment
NCT00247663Phase 2CompletedPrimary
Extension Study of 1.0mg Dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer
Showing all 3 trials
Research Network
Common Treatments
- Letrozole3
Active Sponsors
- Chugai Pharmaceutical3
- Novartis Pharmaceuticals3